HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).

Inclusion Criteria: 1. The patient fully understands this study, voluntarily participates, and signs the informed consent form (ICF); 2. Age ≥18 years; 3. Newly diagnosed with MPAL according to the World Health Organization (WHO) 2022 classification. 4. The patient has not started anti-leukemia treatment after the initial diagnosis (except cytoreductive therapy, such as hydroxyurea or cytarabine \<1.0 g/day or glucocorticoids); 5. Expected survival ≥12 weeks; 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2; 7. Normal cardiac function, left ventricular ejection fraction ≥50%; normal renal function: creatinine clearance ≥30 ml/min; normal liver function: ALT \<5 times the normal value, bilirubin \<3 times the normal value; Exclusion Criteria: 1. Patients who have had or currently have other malignant tumors requiring treatment; 2. Patients with central nervous system (CNS) infiltration; 3. Other clinically significant uncontrolled conditions, including but not limited to: (1) uncontrolled or active systemic infections (viral, bacterial, or fungal); (2) chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment; (3) uncontrolled hypertension, etc.; 4. Patients who cannot take oral medications or have malabsorption syndrome; 5. Patients with a known history of immediate or delayed hypersensitivity reactions to drugs of the same class as the study medication or to excipients; 6. Pregnant or breastfeeding women, or patients who refuse to use effective contraception during the study; 7. Patients with a history of severe neurological or psychiatric disorders who cannot understand or comply with the study protocol; 8. Patients with severe heart disease, such as myocardial infarction, severe or unstable angina, severe arrhythmias; 9. Patients known to be infected with human immunodeficiency virus (HIV); patients with active hepatitis B or C; subjects who are inactive hepatitis carriers or whose viral hepatitis titers are low after treatment with non-prohibited antiviral drugs are not excluded; 10. Patients who cannot take oral medications or have malabsorption syndrome; 11. Patients whom the investigator determines are unsuitable to participate in this study.